GHRP-2 spray is an artificially synthesized hexapeptide compound that stimulates the pulsatile secretion of endogenous growth hormone (GH) by activating the ghrelin receptor (GHS-R1a) in the hypothalamic pituitary axis, mimicking the action of natural ghrelin. As a second-generation growth hormone secretagogue (GHS), it has been widely studied in medical, sports, anti-aging and other fields due to its unique physiological activity. 2-trifluoroethyl)thiazole (GHRP-2) as a new form of preparation, attempts to achieve breakthroughs in improving bioavailability, simplifying operation process and reducing side effects through nasal administration.
Pralmorelin/GHRP-2 COA
1. Medical scenario: Core treatment for growth hormone deficiency
Children's dwarfism: GHRP-2 spray can stimulate pituitary gland to secrete phyone, promote chondrocyte proliferation of bone growth plate, prolong bone age delay and improve final height. A clinical study in Japan showed that after continuous use for 6 months, the annual growth rate of children increased by 2.3cm compared to the control group.
Adult phyone deficiency: Targeting phyone deficiency caused by pituitary injury or disease, it can improve muscle mass, reduce body fat, and optimize metabolic indicators such as blood lipids and blood sugar. In 2012, Sella Pharmaceuticals was approved to sell 2-trifluoroethyl)thiazole nasal spray for such indications.
Postoperative recovery: By promoting collagen synthetise and immune cell activation, it accelerates wound healing and reduces the risk of infection. For example, in patients after joint replacement, combined use of product can shorten the healing time by 30%.
Anti aging scenario: potential intervention measures to delay physiological decline
Skin rejuvenation: stimulates collagen synthetise, increases skin thickness and elasticity, and reduces wrinkle formation. Combined use of antioxidants (such as vitamin C) can significantly improve skin firmness.
Bone density maintenance: By promoting osteoblast activity, inhibiting osteoclast differentiation, and reducing the risk of osteoporosis. It has a protective effect on the bone health of the elderly population or long-term hormone users (such as glucocorticoids).
Cognitive function protection: Animal experiments show that it can reduce the deposition of β - amyloid protein and delay the progress of Alzheimer's disease. It improves memory and cognitive function by optimizing cerebral blood flow and neuronal metabolism.
Core Pathway for Targeted Activation of Pituitary GHS-R1a Receptors
2-trifluoroethyl)thiazole is a growth hormone secretagogue peptide. After mucosal absorption of GHRP-2 spray formulation into systemic circulation, it specifically binds to GHS-R1a, the growth hormone secretagogue receptor located in the anterior pituitary gland. Receptor activation initiates the Gq protein signaling cascade, which stimulates intracellular phospholipase C to decompose phosphatidylinositol into IP3 and diacylglycerol.
IP3 triggers calcium release from the endoplasmic reticulum, rapidly elevating intracellular calcium concentration and stimulating exocytotic release of pituitary growth hormone (phyone) vesicles, thereby acutely raising peripheral serum phyone levels. Unlike GHRH, which only exerts a single secretagogue effect, 2-trifluoroethyl)thiazole can independently trigger phyone secretion and generates synergistic potentiation with endogenous GHRH.
Dual Hypothalamic Regulation of Growth Hormone Secretory Rhythm
The peptide crosses the blood-brain barrier to act on the hypothalamus, exerting bidirectional regulatory effects.
On one hand, it suppresses the synthesis and release of somatostatin (SS), lifting persistent SS-mediated inhibition of pituitary phyone secretion. On the other hand, it boosts hypothalamic GHRH secretion, establishing dual positive stimulation along the hypothalamic-pituitary axis. The sustained mucosal slow-release profile of the spray smooths nocturnal pulsatile phyone peaks and restores disrupted diurnal phyone rhythms in aging and fat-loss populations, avoiding drastic phyone fluctuations induced by single injections.
Downstream Regulatory Mechanisms for Lipid Metabolism and Muscle Anabolism
Elevated phyone stimulates hepatic IGF-1 synthesis to mediate systemic anabolic metabolism. In skeletal muscle, IGF-1 activates the PI3K/Akt pathway and inhibits the ubiquitin-proteasome degradation cascade, reducing muscle protein loss and accelerating myocyte proliferation and differentiation. In adipose tissue, it activates hormone-sensitive lipase to promote lipolysis of visceral and subcutaneous fat, breaking down triglycerides into free fatty acids for energy supply and lowering body fat percentage. It also downregulates insulin resistance-related pro-inflammatory factors to ameliorate disorders of glucose and lipid metabolism.
Unique Absorption-Enhancing Mechanism of Mucosal Spray Formulation
The spray penetrates passively through nasal and oral mucosal epithelia. The abundant mucosal capillaries bypass gastrointestinal peptidase degradation and hepatic first-pass metabolism, delivering markedly higher bioavailability than oral preparations. The small-molecule peptide permeates intercellular mucosal gaps for sustained slow release, stably maintaining therapeutic plasma concentrations and gently stimulating receptors. It avoids abrupt phyone surges associated with injections, lowering adverse reactions such as headache and edema caused by excessive receptor activation.
Auxiliary Molecular Pathways for Anti-Inflammation and Anti-Aging
2-trifluoroethyl)thiazole activates the Nrf2 antioxidant pathway, upregulates superoxide dismutase expression, and eliminates intracellular oxidative free radicals. It suppresses NF-κB inflammatory signaling and reduces levels of pro-inflammatory cytokines including TNF-α and IL-6, alleviating muscle wasting, skin aging and metabolic decline driven by chronic low-grade inflammation. Meanwhile, it preserves osteoblast viability, inhibits osteoclast differentiation, and assists in maintaining bone mineral density.
Breakthrough and Challenge in Nasal Drug Delivery
Traditional GHRP-2 spray formulations are mainly injectable, but there are problems such as complex operation, pain, and local infection risk. The aerosol type is absorbed by the nasal mucosa, trying to achieve improvement in the following aspects:
The nasal mucosa has abundant blood supply, and drugs can directly enter the systemic circulation, bypassing the first pass effect. Research has shown that the bioavailability of 2-trifluoroethyl)thiazole nasal administration can reach 53%, much higher than oral administration (0.3-1%), although still lower than injection (100%), it significantly simplifies the operation process.
The spray type can rapidly penetrate into the mucosa and shorten the onset time of the drug. In animal experiments, the peak time of phyone during nasal administration is 15-20 minutes earlier than that of injection, which is suitable for scenarios that require rapid increase in phyone levels (such as postoperative recovery).
The spray type does not need injection tools, and is easy to operate, especially suitable for children, the elderly or patients who are afraid of injection. For example, 2-trifluoroethyl)thiazole (trade name: GHRP Kaken Nasal) developed by Japanese Kaken Pharma Company has been approved for the treatment of growth hormone deficiency in children.
The spray device can realize single dose standardization (such as 100mcg per spray) through the pump head design, reduce human error and improve treatment safety.
Frontier research and application expansion
In the field of anti-aging, a double-blind trial published in Nature Aging in 2024 showed that continuous use of 2-trifluoroethyl)thiazole (200mcg/day) for 6 months in elderly people aged 65 and above can increase telomerase activity by 18%, muscle strength (grip strength) by 12%, and cognitive function (MMSE score) by 2.1 points (P<0.05).
Trauma repair: In burn patients, 2-trifluoroethyl)thiazole combined with local insulin therapy can shorten wound healing time by 30% and reduce scar formation rate by 45%. The mechanism is related to phyone promoting collagen synthetise and angiogenesis.
High altitude adaptation: Professional athletes using 2-trifluoroethyl)thiazole (300mcg/day) at an altitude of 2500 meters can increase blood oxygen saturation (SpO2) from 88% to 92% and maximum oxygen uptake (VO2max) by 7%.
Future prospects:
Innovative directions from single formulations to combination therapies
Targeted delivery system:
Develop new carriers such as nanoparticles and liposomes, improve the mucosal penetration and targeting of spray, and reduce systemic side effects.
Combination therapy strategy:
Used in combination with GHRH analogs (such as Sermorelin, CJC-1295) to maximize phyone release through synergistic effect.
Personalized medical applications:
Develop personalized dosage plans based on genetic testing (such as GHS-R1a receptor polymorphism) to optimize treatment efficacy and safety.
The Development History of GHRP-2
Background: In the late 1970s to early 1980s, scientists synthesized purified growth hormone releasing peptide for the first time based on the structure of methionine leucine enkephalin. Subsequently, several types of GHRPs were synthesized, laying the foundation for the discovery of 2-trifluoroethyl)thiazole.
Discovery process: In 1993, Dr. CY Bowers from Durham University made a key breakthrough in the field of growth hormone secretagogue and discovered a hexapeptide compound 2-trifluoroethyl)thiazole (also known as KP-102, drug name Pralmorelin). This compound stimulates the release of growth hormone from the anterior pituitary gland by activating the ghrelin receptor (GHSR-1a), mimicking the action of endogenous ghrelin.
Early research: It was found to have a stronger stimulating effect on growth hormone release and improve growth hormone deficiency in children. Its mechanism of action is different from that of growth hormone releasing hormone (GHRH), which can act on pituitary and hypothalamic cells, causing the secretion of growth hormone (phyone) and GHRH.
Clinical trials: In some clinical trials, it has been used to treat children with short stature and has achieved significant therapeutic effects. It can stimulate the pituitary gland to release more growth hormone, promoting children's growth and development.
Drug development: Dr. Bowers collaborated with Kaken Pharmaceuticals to develop 2-trifluoroethyl)thiazole drug. In 2005, Japan was the first to approve its launch under the trade name "GHRP Kaken 100" for the treatment of growth hormone deficiencies such as pituitary dwarfism. In 2012, the US FDA also approved its listing, with Sella Pharmaceuticals responsible for sales.
Multidimensional physiological effects: With the deepening of research, multidimensional physiological effects are gradually being revealed. It not only promotes the secretion of growth hormone, but also has various effects such as metabolic regulation, anti-inflammatory repair, and sleep optimization. For example, in an arthritis model, reducing serum IL-6 levels significantly improves inflammatory symptoms.
Application in the field of fitness: With more research confirming its efficacy, its application is gradually expanding from the medical field to the fitness and bodybuilding market. Athletes and fitness enthusiasts have found that it can become an important auxiliary tool during the muscle building phase by enhancing appetite and promoting muscle growth.
It can increase the levels of serum auxin and IGF-1, enhance the signal expression of related mRNA in the liver and skeletal muscle, thereby promoting protein synthesis and muscle growth.
The applications in the field of anti-aging, such as improving sleep, enhancing immunity, and repairing joints, have also attracted people in need of anti-aging. It is considered a potential anti-aging drug that can delay the aging process and improve quality of life.
Frequently Asked Questions
What are the storage conditions for 2-trifluoroethyl)thiazole?
+
-
Lyophilized 2-trifluoroethyl)thiazole powder is stable at room temperature for short-term storage; long-term sealed storage requires refrigeration at 2–8°C to extend the shelf life. After reconstitution with sterile solvent, it must be stored in a sealed refrigerated environment and used up within 7–10 days to avoid peptide degradation, activity loss and bacterial contamination. Repeated freezing and thawing is strictly prohibited to ensure product activity and purity .
Hot Tags: ghrp-2 spray, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale